Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).

Moreno-Pérez O, Tejera-Muñoz A, Carreño-Valdivia R, Rodríguez-Bedoya M, Guillén-Morote C, Roldán-Sánchez A, Andrés M

Seminars in arthritis and rheumatism7 Aug 2025

PMID40816061DOI10.1016/j.semarthrit.2025.152807PepBankPUB-40816061

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on oral semaglutide, 76% had serum urate below 6 mg/dL at 12 months (primary endpoint), against 66.1% at baseline.
In plain wordsIn adults with type 2 diabetes on oral semaglutide, 76% had healthy urate levels at 12 months, with no control group.
Peptide
Semaglutide
Outcome
IncreaseProportion with serum urate below 6 mg/dL at 12 months
Study
n = 236
Analysis
Primary
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
Proportion with SU <6 mg/dL
76%
12 months
Proportion with SU <6 mg/dL
66.1%
baseline
Source sentences
Summary
Under oral semaglutide, 70.7 % and 76 % showed SU <6 mg/dL at 6 and 12 months, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was achieving SU levels below 6 mg/dL at 12 months of follow-up (FU).
Summary · context
Baseline SU was 5.2 mg/dL, 66.1 % had SU levels <6 mg/dL, and 23.7 % had hyperuricemia.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606102
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum urate decreased by 0.1 mg/dL after 6 months of oral semaglutide, which was not significant (p = 0.52).
In plain wordsIn adults with type 2 diabetes, urate did not change significantly after 6 months of oral semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSerum urate change at 6 months
Study
n = 236
Analysis
Secondary
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
Change in serum urate
−0.1 mg/dL
6 months
Source sentences
Summary
SU decreased by 0.1 mg/dL after 6 months (p = 0.52) and by 0.2 mg/dL (p = 0.01) at 12 months FU.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondly, we assessed baseline factors associated with achieving SU levels of <6 mg/dL and average reductions in SU levels.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606103
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum urate decreased by 0.2 mg/dL (p = 0.01) after 12 months of oral semaglutide.
In plain wordsIn adults with type 2 diabetes, urate fell slightly after 12 months of oral semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseSerum urate change at 12 months
Study
n = 236
Analysis
Secondary
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
Change in serum urate
−0.2 mg/dL
12 months
Source sentences
Summary
by 0.2 mg/dL (p = 0.01) at 12 months FU.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondly, we assessed baseline factors associated with achieving SU levels of <6 mg/dL and average reductions in SU levels.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606104
04HumanObservational studyEfficacy outcome
In patients with baseline serum urate above 6 mg/dL, reductions were greater: 0.6 mg/dL at 6 months and 0.8 mg/dL at 12 months (all p < 0.001).
In plain wordsIn people with higher urate at the start, oral semaglutide was linked to larger falls in urate, with no control group.
Peptide
Semaglutide
Outcome
DecreaseSerum urate change in patients with baseline urate above 6 mg/dL
Study
n: not reported in source
Analysis
Secondary
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
Change in serum urate
−0.6 mg/dL
6 months, baseline SU >6 mg/dL
Change in serum urate
−0.8 mg/dL
12 months, baseline SU >6 mg/dL
Source sentences
Summary
Greater reductions were observed in those with baseline SU >6 mg/dL (0.6 mg/dL and 0.8 mg/dl, respectively; all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606105
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on oral semaglutide, 70.7% had serum urate below 6 mg/dL at 6 months, against 66.1% at baseline.
In plain wordsIn adults with type 2 diabetes on oral semaglutide, most had healthy urate levels at 6 months, with no control group.
Peptide
Semaglutide
Outcome
IncreaseProportion with serum urate below 6 mg/dL at 6 months
Study
n = 236
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
Proportion with SU <6 mg/dL
70.7%
6 months
Proportion with SU <6 mg/dL
66.1%
baseline
Source sentences
Summary
Under oral semaglutide, 70.7 % and 76 % showed SU <6 mg/dL at 6 and 12 months, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Baseline SU was 5.2 mg/dL, 66.1 % had SU levels <6 mg/dL, and 23.7 % had hyperuricemia.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606101
06HumanObservational studyOther
In adults on oral semaglutide, baseline serum urate of 7 mg/dL or more was associated with reaching the urate target (OR 4.54, 95% CI 1.08-19.25).
In plain wordsIn adults on oral semaglutide, a high starting urate level was linked to reaching a healthy urate level.
Peptide
Semaglutide
Outcome
Not applicableBaseline serum urate of 7 mg/dL or more as predictor of reaching urate below 6 mg/dL
Study
n = 236
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
OR
4.54 ratio
baseline SU >=7 mg/dL
95% CI
1.08 to 19.25 ratio
baseline SU >=7 mg/dL
Source sentences
Summary
After multivariate adjustment, only SU ≥7 mg/dL (OR 4.54, 95 %CI 1.08-19.25) and switching from a DPP-4 inhibitor (OR 6.53, 95 %CI 1.57-27.32) were associated with achieving the SU target.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondly, we assessed baseline factors associated with achieving SU levels of <6 mg/dL and average reductions in SU levels.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606106
07HumanObservational studyOther
In adults on oral semaglutide, switching from a DPP-4 inhibitor was associated with reaching the urate target (OR 6.53, 95% CI 1.57-27.32).
In plain wordsIn adults on oral semaglutide, switching from a DPP-4 inhibitor was linked to reaching a healthy urate level.
Peptide
Semaglutide
Outcome
Not applicableSwitching from a DPP-4 inhibitor as predictor of reaching urate below 6 mg/dL
Study
n = 236
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Measurements
OR
6.53 ratio
switch from DPP-4 inhibitor
95% CI
1.57 to 27.32 ratio
switch from DPP-4 inhibitor
Source sentences
Summary
After multivariate adjustment, only SU ≥7 mg/dL (OR 4.54, 95 %CI 1.08-19.25) and switching from a DPP-4 inhibitor (OR 6.53, 95 %CI 1.57-27.32) were associated with achieving the SU target.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondly, we assessed baseline factors associated with achieving SU levels of <6 mg/dL and average reductions in SU levels.
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606107
08HumanObservational studyMechanism
In adults on oral semaglutide, changes in serum urate were independent of improved metabolic control, weight loss, or baseline use of GLP-1 RAs or SGLT2 inhibitors.
In plain wordsIn adults on oral semaglutide, urate changes did not depend on better blood sugar control, weight loss or earlier use of other diabetes drugs.
Peptide
Semaglutide
Outcome
No significant changeIndependence of urate change from metabolic control, weight loss and baseline drug use
Study
n = 236
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Changes in SU levels were independent of improved metabolic control, weight loss, or baseline use of GLP-1 RAs or SGLT2 inhibitors.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational study including PWT2D who were prescribed oral semaglutide.
Summary · context
The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors).
Report a problemFND-4081606108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords